乙型肝炎病毒感染与弥漫大B细胞淋巴瘤预后的相关性分析  

Analysis on the correlation between the prognosis of patients with diffuse large B-cell lymphoma and HBV infection

作　　者：张文军[1] 王丽[2] 李启英[1] 杨涛[1] 项颖[1] 

机构地区：[1]重庆市肿瘤研究所血液肿瘤及生物治疗科,重庆400030 [2]重庆市中山医院肿瘤科,重庆400010

出　　处：《中国肿瘤临床与康复》2014年第7期807-809,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨乙型肝炎病毒(HBV)感染与弥漫大B细胞淋巴瘤(DLBCL)预后的相关性。方法选取乙型肝炎表面抗原(HBsAg)阳性和HBsAg阴性的初治DLBCL患者各60例,均给予化疗,比较分析两组患者化疗期间的肝功能以及随访2年后的无进展生存时间(PFS)和总生存时间(OS)。结果 HBsAg阳性组和HBsAg阴性组患者化疗期间的肝功能损害发生率分别为66.0%和40.0%,差异有统计学意义(P<0.05)。HBsAg阳性组患者的PFS为(16.1±3.2)个月,PFS率为70.0%,OS率为85.0%;HBsAg阴性组患者的PFS为(17.3±4.1)个月,PFS率为73.0%,OS率为88.0%,两组差异无统计学意义(P>0.05)。结论 HBV感染与DLBCL患者的预后无关,但合并HBV感染会增加DLBCL患者在化疗期间肝功能损害的发生率。Objective To investigate the correlation between prognosis of patients with diffuse large B-cell lymphoma（DLBCL） and hepatitis B virus（HBV） infection. Methods 60 HBsAg-positive patients and 60 HBsAg-negative patients with DLBCL were selected, all of the patients were treated by chemothera- py. The liver function during the chemotherapy, the progression-free survival time （PFS） and overall survival time（OS） in the followed 2 years were observed and compared between the two groups. Results The liver function damage rates during chemotherapy of HBsAg-positive group and HBsAg-negative group were 66.0% and 40. 0% ,respectively（P 〈 0. 05 ）. The 2-year PFS in the HBsAg-positive group was （ 16. 1 ＋ 3.2） months,with a PFS rate of 70. 0% and an OS rate of 85.0%. In the HBsAg-negative group the PFS was （ 17.3 ~ 4. 1 ） months,the PFS rate was 73.0% and the OS rate was 88.0% ,which were consistent with the HBsAg-postive group（P 〉 0. 05）. Conclusion The HBV infection had no significant impaction on clinical features and prognosis in patients with DLBCL, but it can increase the risk of liver damage during the chemotherapy.

关 键 词：弥漫大B细胞淋巴瘤 乙型肝炎病毒 预后 

分 类 号：R733.1[医药卫生—肿瘤]